lysine methyltransferase 2D
Zuletzt aktualisiert 26 Sept 2025
Erfüllt die redaktionelle Richtlinien
- HerunterladenHerunterladen
- Teilen
- Language
- Diskussion
- Audio-Version
- Zu bevorzugten Quellen bei Google hinzufügen
Der KMT2D gene, also known as MLL2, provides instructions for making an enzyme called lysine-specific methyltransferase 2D that is found in many organs and tissues of the body. Lysine-specific methyltransferase 2D functions as a histone methyltransferase. Histone methyltransferases are enzymes that modify proteins called histones. Histones are structural proteins that attach (bind) to DNA and give chromosomes their shape. By adding a molecule called a methyl group to histones (a process called methylation), histone methyltransferases control (regulate) the activity of certain genes. Lysine-specific methyltransferase 2D appears to activate certain genes that are important for development.
Normal function
Der KMT2D gene, also known as MLL2, provides instructions for making an enzyme called lysine-specific methyltransferase 2D that is found in many organs and tissues of the body. Lysine-specific methyltransferase 2D functions as a histone methyltransferase. Histone methyltransferases are enzymes that modify proteins called histones. Histones are structural proteins that attach (bind) to DNA and give chromosomes their shape. By adding a molecule called a methyl group to histones (a process called methylation), histone methyltransferases control (regulate) the activity of certain genes. Lysine-specific methyltransferase 2D appears to activate certain genes that are important for development.
Lysine-specific methyltransferase 2D is also believed to act as a tumour suppressor, which means it normally helps prevent cells from growing and dividing in an uncontrolled way.
Conditions referring to this gene or chromosome
Other names
AAD10
ALL1-related protein
ALR
CAGL114
histone-lysine N-methyltransferase MLL2
KMT2B
lysine (K)-specific methyltransferase 2D
lysine N-methyltransferase 2B
MLL2
MLL2_HUMAN
MLL4
myeloid/lymphoid or mixed-lineage leukemia 2
TNRC21
trinucleotide repeat containing 21
Related patient information and medicines
Patient information leaflet
Parkinson-Krankheit
The main symptoms of Parkinson's disease are usually stiffness, shaking (tremor), and slowness of movement. People with Parkinson's may also develop other symptoms (listed below). Sometimes these medicines are used in combination with levodopa in the later stages of PD. Other medicines used for PD Catechol-O-methyltransferase (COMT) inhibitors are.
Medicine leaflet
Tioguanin
You will be prescribed tioguanine by a doctor who specialises in cancer treatment. Tioguanin is a treatment used for acute myeloid leukaemia (AML) , acute lymphoblastic Leukämie (ALL) , and chronic myeloid leukaemia (CML). If you have ever been told by a doctor that you lack certain enzymes... In particular, tell your doctor if you know your.
Medicine leaflet
Aspirin und Metoclopramid bei Migräne
MigraMax® helps to ease headache and Übelkeit (nausea and vomiting) during a migraine or during treatment with chemotherapy o... About aspirin and metoclopramide Type of medicine A painkiller with an anti-emetic Used for The treatment of migraine symptoms; prevention of nausea and vomiting caused by chemotherapy or radiotherapy Also called.
Medicine leaflet
Entacapon bei Parkinson-Krankheit
Your doctor will ... About entacapone Type of medicine A dopaminergic medicine called a catechol-O-methyltransferase inhibitor Used for Parkinson's disease Also called Comtess®; Combination brands: Stalevo®, Sastravi®, Stanek®, Lecigon® (entacapone with levodopa and carbidopa [ co-careldopa ]) Available as Tablets Parkinson's disease affects the.
Medicine leaflet
Tolcapon bei Parkinson-Krankheit
You should tell your doctor immediately if you lose your appetite, feel sick or have pain in your tummy (abdomen), develop dark-coloured ur... About tolcapone Type of medicine A dopaminergic medicine called a catechol-O-methyltransferase inhibitor Used for Parkinson's disease Also called Tasmar® Available as Tablets Parkinson's disease affects the.
Medicine leaflet
Mercaptopurin
You will be prescribed Mercaptopurin by a specialist Krebs doctor. Your doctor will discuss with you the possibility of unwanted side... About Mercaptopurin Type of medicine An antimetabolite anti-cancer medicine Used for Treatment of leukaemia Also called Xaluprine®; Hanixol® Available as Tablets and oral liquid medicine Leukaemia is a cancer.
Weiterführende Lektüre und Referenzen
- lysine methyltransferase 2D; MedlinePlus, National Library of Medicine.
- Bogershausen N, Wollnik B. Unmasking Kabuki syndrome. Clin Genet. 2013 Mar;83(3):201-11. doi: 10.1111/cge.12051. Epub 2012 Nov 26.
- Dentici ML, Di Pede A, Lepri FR, Gnazzo M, Lombardi MH, Auriti C, Petrocchi S, Pisaneschi E, Bellacchio E, Capolino R, Braguglia A, Angioni A, Dotta A, Digilio MC, Dallapiccola B. Kabuki syndrome: clinical and molecular diagnosis in the first year of life. Arch Dis Child. 2015 Feb;100(2):158-64. doi: 10.1136/archdischild-2013-305858. Epub 2014 Oct 3.
- Liu S, Hong X, Shen C, Shi Q, Wang J, Xiong F, Qiu Z. Kabuki syndrome: a Chinese case series and systematic review of the spectrum of mutations. BMC Med Genet. 2015 Apr 21;16:26. doi: 10.1186/s12881-015-0171-4.
- Micale L, Augello B, Maffeo C, Selicorni A, Zucchetti F, Fusco C, De Nittis P, Pellico MT, Mandriani B, Fischetto R, Boccone L, Silengo M, Biamino E, Perria C, Sotgiu S, Serra G, Lapi E, Neri M, Ferlini A, Cavaliere ML, Chiurazzi P, Monica MD, Scarano G, Faravelli F, Ferrari P, Mazzanti L, Pilotta A, Patricelli MG, Bedeschi MF, Benedicenti F, Prontera P, Toschi B, Salviati L, Melis D, Di Battista E, Vancini A, Garavelli L, Zelante L, Merla G. Molecular analysis, pathogenic mechanisms, and readthrough therapy on a large cohort of Kabuki syndrome patients. Hum Mutat. 2014 Jul;35(7):841-50. doi: 10.1002/humu.22547. Epub 2014 Apr 9.
- Natarajan TG, Kallakury BV, Sheehan CE, Bartlett MB, Ganesan N, Preet A, Ross JS, FitzGerald KT. Epigenetic regulator MLL2 shows altered expression in cancer cell lines and tumors from human breast and colon. Cancer Cell Int. 2010 Apr 30;10:13. doi: 10.1186/1475-2867-10-13.
- Ng SB, Bigham AW, Buckingham KJ, Hannibal MC, McMillin MJ, Gildersleeve HI, Beck AE, Tabor HK, Cooper GM, Mefford HC, Lee C, Turner EH, Smith JD, Rieder MJ, Yoshiura K, Matsumoto N, Ohta T, Niikawa N, Nickerson DA, Bamshad MJ, Shendure J. Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. Nat Genet. 2010 Sep;42(9):790-3. doi: 10.1038/ng.646. Epub 2010 Aug 15.
- Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, Boca SM, Carter H, Samayoa J, Bettegowda C, Gallia GL, Jallo GI, Binder ZA, Nikolsky Y, Hartigan J, Smith DR, Gerhard DS, Fults DW, VandenBerg S, Berger MS, Marie SK, Shinjo SM, Clara C, Phillips PC, Minturn JE, Biegel JA, Judkins AR, Resnick AC, Storm PB, Curran T, He Y, Rasheed BA, Friedman HS, Keir ST, McLendon R, Northcott PA, Taylor MD, Burger PC, Riggins GJ, Karchin R, Parmigiani G, Bigner DD, Yan H, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE. The genetic landscape of the childhood cancer medulloblastoma. Science. 2011 Jan 28;331(6016):435-9. doi: 10.1126/science.1198056. Epub 2010 Dec 16.
- Paulussen AD, Stegmann AP, Blok MJ, Tserpelis D, Posma-Velter C, Detisch Y, Smeets EE, Wagemans A, Schrander JJ, van den Boogaard MJ, van der Smagt J, van Haeringen A, Stolte-Dijkstra I, Kerstjens-Frederikse WS, Mancini GM, Wessels MW, Hennekam RC, Vreeburg M, Geraedts J, de Ravel T, Fryns JP, Smeets HJ, Devriendt K, Schrander-Stumpel CT. MLL2 mutation spectrum in 45 patients with Kabuki syndrome. Hum Mutat. 2011 Feb;32(2):E2018-25. doi: 10.1002/humu.21416. Epub 2010 Dec 7.
Artikelverlauf
Artikel auch verfügbar in Englisch, Deutsch, Spanisch, Französisch, Italienisch, Portugiesisch, Hindi, Hebräisch, Arabisch, und Schwedisch.
26 Sept 2025 | Neueste Version
1 Oct 2013 | Ursprünglich veröffentlicht
Nehmen Sie an der Diskussion teil
Teilen Sie Ihre Gedanken oder Erfahrungen mit anderen in unserem Patientengemeinschaften.
Fragen, teilen, verbinden.
Durchsuchen Sie Diskussionen, stellen Sie Fragen und teilen Sie Erfahrungen zu Hunderten von Gesundheitsthemen.
Abonnieren Sie den Patienten-Newsletter
Ihre wöchentliche Dosis klarer, vertrauenswürdiger Gesundheitsberatung - geschrieben, um Ihnen zu helfen, sich informiert, selbstbewusst und in Kontrolle zu fühlen.
Durch das Abonnieren akzeptieren Sie unsere Datenschutzrichtlinie. Sie können sich jederzeit abmelden. Wir verkaufen Ihre Daten niemals.